interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Carmustine

Generic competition · all medicines · read 12 November 2026

Is there a generic of Carmustine, and who makes it?

Carmustine appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 7 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Carmustine3 dosage-form groups in the Orange Book
7generic makers listed
  1. Carmustine appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 7 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Injectable, Injection

Four or more generic makers listed

Brand listed as marketed: Bicnu. 7 generic makers with 7 generic products listed as marketed; the first generic approval is dated 11 September 2018.

201520202025203007Navinta Llc, first approval 11 September 2018Amneal Eu Ltd, first approval 16 October 2018Penn Life Sciences Llc, first approval 2 April 2019Dr Reddys Laboratories Ltd, first approval 22 October 2020Meitheal Pharmaceuticals Inc, first approval 2 August 2021Msn Laboratories Private Ltd, first approval 11 May 2023Alembic Pharmaceuticals Ltd, first approval 20 October 2023data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Navinta Llc11 September 20181
Amneal Eu Ltd16 October 20181
Penn Life Sciences Llc2 April 20191
Dr Reddys Laboratories Ltd22 October 20201
Meitheal Pharmaceuticals Inc2 August 20211
Msn Laboratories Private Ltd11 May 20231
Alembic Pharmaceuticals Ltd20 October 20231

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Powder, Intravenous

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

20202025203001brand 2022data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Implant, Intracranial

Brand listed, no generic listed as marketed

Brand listed as marketed: Gliadel. No generic is listed as marketed.

1995200020052010201520202025203001brand 1996data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.